On Tuesday, 'Mint' had reported that the Canadian drug regulator, Health Canada, has sent a "regulatory letter" to Ranbaxy Pharmaceuticals Canada Inc., a wholly-owned subsidiary of Ranbaxy and the sole importer of its products in Canada, requesting an action plan and a response to the warning letter issued by USFDA.